8-K current report · filed Nov 5, 2026

aTYR PHARMA INC (ATYR) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1ATYR overview

Short answer

aTYR PHARMA INC (ATYR) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers aTyr Pharma’s quarter ended September 30, 2026.

aTYR PHARMA INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers aTyr Pharma’s quarter ended September 30, 2026
  • Financial results and management commentary available in Exhibit 99.1
  • Quarterly disclosure provides investors an update on operating performance and financial condition

Item EX-99.1 · Exhibit EX-99.1

  • FDA-aligned Phase 3 efzofitimod protocol, using FVC as primary endpoint, moves pulmonary sarcoidosis program toward pivotal testing
  • Strategic partnerships or licensing now prioritized, creating execution and funding dependence on external financing or collaboration
  • EFZO-CONNECT Phase 2 enrollment completed, with systemic sclerosis ILD results expected in Q2 2027
  • Cash and investments $50.3M at September 30, 2026, supporting operations into late 2028 under current plans
  • Q3 net loss $18.3M, R&D expense $10.4M, and G&A expense $8.3M; cash declined from $80.9M at December 31, 2025

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other aTYR PHARMA INC 8-K filings

Get the next ATYR 8-K as it lands

Follow ATYR for push alerts, or ask the research agent what this filing means.